Eligible 12-15 Year Olds:

Updated: 18th August 2021

We are currently arranging to offer a date for a 1st dose Pfizer vaccine for eligible 12-15 year olds prior to them going back to school. 

Useful link for children and young people: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1008730/PHE_12124_COVID-19_vaccination_for_at_risk_CYP_simple_text_leaflet.pdf

**Please avoid phoning the practie in relation to a COVID vaccine query. Please e-mail us at: [email protected] 

The eligibility for this cohort, as set out by the JCVI, is as follows:

Individuals aged 12 years or above at higher risk of severe COVID-19 infection.


This includes those with:
● severe neuro-disability and/or neuromuscular conditions that compromise respiratory
function. This includes conditions (such as cerebral palsy, autism and muscular dystrophy)
that may affect swallowing and protection of the upper airways, leading to aspiration,
and reduce the ability to cough and resulting overall in increased susceptibility to
respiratory infections
● children and young adults with learning disability (LD), including:

  • individuals with Down’s syndrome
  • those who are on the learning disability register
  • those with profound and multiple learning disabilities (PMLD) or severe LD
    ● immunosuppression due to disease or treatment, including:
  • patients undergoing chemotherapy leading to immunosuppression, patients undergoing
    radical radiotherapy, solid organ transplant recipients, bone marrow or stem cell
    transplant recipients, HIV infection at all stages or genetic disorders affecting the
    immune system (e.g. IRAK-4, NEMO, complement disorder, SCID)
  • individuals who are receiving immunosuppressive or immunomodulating biological
    therapy including, but not limited to, anti-TNF, alemtuzumab, ofatumumab, rituximab,
    patients receiving protein kinase inhibitors or PARP inhibitors, and individuals treated
    with steroid sparing agents such as cyclophosphamide and mycophenolate mofetil
  • individuals treated with or likely to be treated with systemic steroids for more than a
    month at a dose equivalent to prednisolone at 20mg per day (or for children under
    20kg body weight a dose of 1mg/kg or more per day).
  • anyone with a history of haematological malignancy, including leukaemia, lymphoma,
    and myeloma and those with auto-immune diseases who may require long term
    immunosuppressive treatments
  • Individuals aged over 12 years who are contacts of immunosuppressed individuals
    Those aged 12 years and above who expect to share living accommodation on most days
    (and therefore for whom continuing close contact is unavoidable) with individuals of any age who are immunosuppressed
  • Current Green book guidelines define immunosupressed as:

Immunosuppression due to disease or treatment, including patients
undergoing chemotherapy leading to immunosuppression, patients
undergoing radical radiotherapy, solid organ transplant recipients, bone
marrow or stem cell transplant recipients, HIV infection at all stages,
multiple myeloma or genetic disorders affecting the immune system (e.g.
IRAK-4, NEMO, complement disorder, SCID).


Individuals who are receiving immunosuppressive or immunomodulating
biological therapy including, but not limited to, anti-TNF, alemtuzumab,
ofatumumab, rituximab, patients receiving protein kinase inhibitors or
PARP inhibitors, and individuals treated with steroid sparing agents such as
cyclophosphamide and mycophenolate mofetil.
Individuals treated with or likely to be treated with systemic steroids for
more than a month at a dose equivalent to prednisolone at 20mg or more
per day for adults.


Anyone with a history of haematological malignancy, including leukaemia,
lymphoma, and myeloma and those with systemic lupus erythematosus
and rheumatoid arthritis, and psoriasis who may require long term
immunosuppressive treatments.